55 results
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
15 May 24
Avenue Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
9:01am
and future laws and regulations relating to fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare
424B3
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement
4:53pm
of current and future laws and regulations relating to fraud and abuse, false claims, transparency, health information privacy and security, and other
424B5
ATXI
Avenue Therapeutics Inc
10 May 24
Prospectus supplement for primary offering
4:52pm
information privacy and security, and other healthcare laws and regulations;
the effects of competition for our product candidates and the potential for new
8-K
EX-99.1
ATXI
Avenue Therapeutics Inc
1 May 24
Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
4:28pm
claims, transparency, health information privacy and security, and other healthcare laws and regulations; the effects of competition for our product
8-K
EX-99.1
jlrfqp4dr2798
26 Apr 24
Avenue Therapeutics Announces Reverse Stock Split
4:39pm
8-K
EX-99.1
ylulzvff8ug
18 Mar 24
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
4:10pm
424B3
k0g6j 2k3ci6fkr
2 Feb 24
Prospectus supplement
12:00am
8-K
EX-10.2
45nsvx
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
h1c d04c6a45t9j2ep
2 Nov 23
Prospectus supplement with pricing info
9:00am
FWP
rh1542f
5 Oct 23
Free writing prospectus
5:05pm
FWP
9vuoo
3 Oct 23
Free writing prospectus
5:47pm